1010 related articles for article (PubMed ID: 28667006)
21. Development and validation of a CpG island methylator phenotype-related prognostic signature for cholangiocarcinoma.
Liang J; Liu T; Liao J; Zhang L; Zhou M; Xu W; He Y; Cai G; Jin G; Song J; Li G; Liang H; Ding Z; Zhang B
J Cell Physiol; 2021 Apr; 236(4):3143-3156. PubMed ID: 32996133
[TBL] [Abstract][Full Text] [Related]
22. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.
Wang XY; Zhu WW; Wang Z; Huang JB; Wang SH; Bai FM; Li TE; Zhu Y; Zhao J; Yang X; Lu L; Zhang JB; Jia HL; Dong QZ; Chen JH; Andersen JB; Ye D; Qin LX
Theranostics; 2022; 12(1):260-276. PubMed ID: 34987644
[No Abstract] [Full Text] [Related]
23. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Ang C
J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
Likhitrattanapisal S; Tipanee J; Janvilisri T
Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
[TBL] [Abstract][Full Text] [Related]
25.
Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
[TBL] [Abstract][Full Text] [Related]
26. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic alterations associated with cholangiocarcinoma (review).
Isomoto H
Oncol Rep; 2009 Aug; 22(2):227-32. PubMed ID: 19578760
[TBL] [Abstract][Full Text] [Related]
29. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing.
Isomoto H
Digestion; 2009; 79 Suppl 1():2-8. PubMed ID: 19153483
[TBL] [Abstract][Full Text] [Related]
31. Molecular aspects of cholangiocarcinoma.
Kiguchi K
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
[TBL] [Abstract][Full Text] [Related]
32. Role of epigenetic alterations in cholangiocarcinoma.
Tischoff I; Wittekind C; Tannapfel A
J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
34. Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
Goeppert B; Toth R; Singer S; Albrecht T; Lipka DB; Lutsik P; Brocks D; Baehr M; Muecke O; Assenov Y; Gu L; Endris V; Stenzinger A; Mehrabi A; Schirmacher P; Plass C; Weichenhan D; Roessler S
Hepatology; 2019 May; 69(5):2091-2106. PubMed ID: 30615206
[TBL] [Abstract][Full Text] [Related]
35. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.
Nepal C; O'Rourke CJ; Oliveira DVNP; Taranta A; Shema S; Gautam P; Calderaro J; Barbour A; Raggi C; Wennerberg K; Wang XW; Lautem A; Roberts LR; Andersen JB
Hepatology; 2018 Sep; 68(3):949-963. PubMed ID: 29278425
[TBL] [Abstract][Full Text] [Related]
36. Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma.
Nanok C; Jearanaikoon P; Proungvitaya S; Limpaiboon T
Mol Med Rep; 2018 Mar; 17(3):4145-4153. PubMed ID: 29359783
[TBL] [Abstract][Full Text] [Related]
37. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
Mahipal A; Tella SH; Kommalapati A; Anaya D; Kim R
Cancer Treat Rev; 2019 Aug; 78():1-7. PubMed ID: 31255945
[TBL] [Abstract][Full Text] [Related]
38. Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma.
Shu Y; Wang B; Wang J; Wang JM; Zou SQ
World J Gastroenterol; 2011 Aug; 17(29):3407-19. PubMed ID: 21876633
[TBL] [Abstract][Full Text] [Related]
39. Epigenome Remodeling in Cholangiocarcinoma.
O'Rourke CJ; Lafuente-Barquero J; Andersen JB
Trends Cancer; 2019 Jun; 5(6):335-350. PubMed ID: 31208696
[TBL] [Abstract][Full Text] [Related]
40. Cholangiocarcinoma Insights: Established Foundations and Cutting-Edge Innovations from Dr. James Cleary's Pioneering Research.
Cortiana V; Chorya H; Joshi M; Kannan S; Mahendru D; Vallabhaneni H; Coloma HS; Leyfman Y; Park CH
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]